Chronic Hepatitis B Drug Development Summit
5-6 May, 2021
Pietro Scalfaro, our CMO, will present clinical results of our lead compound Vonafexor at the Chronic Hepatitis B Drug Development Summit : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”.
This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug development in Chronic HBV. The two-day program explores the full spectrum of antiviral & immunomodulatory agents being investigated to achieve a functional cure in chronic HBV infection & mitigate related conditions such as fibrosis, cirrhosis, & hepatocellular carcinoma.
More details here: https://chronic-hbv-summit.com/
Read next in 'Events'
- The 2024 international workshop on Alport syndrome
- ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
- 6th CKD Summit – Chronic Kidney Disease Drug Development
- ASN Kidney Week
- Alport Connect 2023, the annual Alport syndrome patient and family meeting in US